Fundraising FoxCity Hill Ventures — Full Portfolio
4 tracked investments · listed companies and verified rows first
Boundless Bio develops precision oncology medicines targeting ecDNA-amplified cancers, specifically creating a new category of ecDNA-directed therapies for patients with oncogenic alterations.
BiotechMedical DevicesLa Jolla, US
Zachary D. Hornby(Executive Officer, Director)inRobert Doebele(Chief Medical Officer)inChristian Hassig(Chief Scientific Officer)Jessica Oien(Chief Legal Officer and Corporate Secretary)in
BoardBenjamin Cravatt, Ph.D.(Director)Kristina Burow(Director)in
Co-investorsARCH Venture PartnersNextech InvestRA CapitalWellington ManagementAlexandriaNEXTECH ONCOLOGY SCSP+4 more
Erasca is a clinical-stage oncology company developing therapies targeting RAS- and MAPK pathway-driven cancers using a modality-agnostic approach including small molecules, large molecules, and protein degraders.
BiotechDeep TechDigital HealthMedical DevicesSan Diego, US
Jonathan E. Lim, M.D.(Chairman, CEO and Co-founder)Gary Yeung, CFA(Chief Business Officer)in
BoardAlexander W. Casdin(Director)Pratik S. Multani, M.D.(Director)Valerie Harding-Start(Director)James A. Bristol, Ph.D.(Director)
Co-investorsAndreessen HorowitzARCH Venture PartnersColt VenturesEvolution VC PartnersFrazier Life SciencesLifeSci Venture Partners+1 more
Maze Therapeutics develops precision medicines for common diseases with high unmet need, using its Compass platform based on human genetics and variant functionalization.
AI & Machine LearningBiotechSouth San Francisco, US
Charles Homcy(Director)Jason Coloma(Chief Executive Officer)in
Co-investorsAndreessen HorowitzARCH Venture PartnersForesite CapitalFrazier Life SciencesGV (Google Ventures)Hercules Capital, Inc.+9 more
BiotechPhoenix, US
Douglas Grant McFadden, Ph.D.(Director)Steven J. Potts, Ph.D.(President and Chief Executive Officer)Ting Xiao(Director)Jason Rushton(Director)Kanad Das, Ph.D.(Director)Michael G. Wood(Executive Officer)
Co-investorsXeraya CapitalB Capital GroupBoehringer Ingelheim Venture FundDelos CapitalKorea Investment PartnersLumira Ventures+1 more
.jpeg){kind=logo}
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.